About: Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 1971

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 1971 (uk) artículu científicu espublizáu n'avientu de 1971 (ast) im Dezember 1971 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 December 1971 (en)
publication date	wds:Q69957238-E42CA862-0305-4EE3-A09E-2560E814D4DF
publication date	1971-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q69957238-AA31893D-F33E-4F2E-96B7-30D384497189
language of work or name	English
author name string	wds:Q69957238-3D005634-CBB5-4ACD-908D-50FE631C944D wds:Q69957238-42CA498A-FAD6-4BB1-930B-984F27FA1687
author name string	M F Oliver H A Dewar
rdfs:label	Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials (en) Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials (nl)
skos:prefLabel	Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials (en) Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials (nl)
name	Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials (en) Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials (nl)
title	wds:Q69957238-D9484C00-6895-4A0A-9688-2BEDCDC38F06
title	Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials (en)
page(s)	wds:Q69957238-4B4A3D09-B63F-4FCD-B457-CF320979C93D
page(s)	784-786
instance of	wds:Q69957238-509EBF48-0BEB-45F8-B354-446153B50C86
instance of	scholarly article
PubMed ID	wds:Q69957238-485D081C-228C-4A96-8345-C4FBE50C5D90
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4943607
PubMed ID	4943607
published in	wds:Q69957238-D27D6DD2-C016-48F8-A2D0-47AD36F0483D
published in	BMJ - General Practice Edition
issue	wds:Q69957238-4341D400-0FF6-4054-B47C-D203D2256D42
volume	wds:Q69957238-188966EC-4332-441C-9520-350931FCB37F
issue	5790
volume	4
DOI	wds:Q69957238-C9511C98-1928-4E3D-9763-A0D5F280CD9F
DOI	http://dx.doi.org/10.1136/BMJ.4.5790.784
DOI	10.1136/BMJ.4.5790.784
PMCID	wds:Q69957238-9D3E2390-5CB9-4770-96A8-F3691CC23161
PMCID	1799699
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q69957238
is cites work of	A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators The protective action of essential oils of onion and garlic in cholesterol-fed rabbits The Effect of Clofibrate on Glucose Tolerance, Insulin Secretion, Triglycerides and Fibrinogen in Patients with Coronary Heart Disease Hyperlipidaemia and deafness: a preliminary survey The hyperlipoproteinemias. Detection, diagnosis, and management Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man Lack of impact of prevention on sudden cardiac death Secondary prevention after myocardial infarction: subgroup analysis of patients at risk in the Norwegian Timolol Multicenter Study Changes produced by clofibrate in hepatocytes of rats with sucrose-induced hyperlipidemia The clofibrate saga: a retrospective commentary Therapy of lipid disorders The care of the patient with coronary heart disease. Report of a Joint Working Party of the Royal College of Physicians of London and the British Cardiac Society Pioneer research in Britain into atherosclerosis and coronary heart disease--an historical review Cholesterol trials and mortality Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies Results of Ankle Systolic Pressure Measurements in Patients With Intermittent Claudication Being Treated With Clofibrate Drug treatment of primary hyperlipoproteinemia (author's transl) Hypolipidaemic aryloxyacetic acids Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease Effects of S-8527 (1, 1-BIS [4’-(l”-Carboxy-L”-Methylpropoxy) Phenyl] Cyclohexane), A New Hypolipidemic Compound, on Platelet Aggregation, Adhesiveness and Blood Coagulation in Rats Hypolipaemic drugs and coronary heart disease Why measure cholesterol after myocardial infarction, and when? The importance of plasma fibrinogen in vascular surgery Sulphinpyrazone, cardiac infarction, and the prevention of death: a successful trial or another tribulation? Planning the Type II Coronary Primary Prevention Trial of the Lipid Research Clinics (U. S. A.) Confusion with clofibrate Familial type II hyperlipoproteinaemia in a Chinese family Clofibrate and the primary prevention of ischaemic heart disease Prognosis of Angina Pectoris Antidepressants and the developing nervous system Therapeutic progress--Review III. Can drugs prevent recurrent myocardial infarction? Who is for cholesterol testing?
is cites work of	wds:Q30499093-2AF1F463-4EAC-414E-ADBE-DD06977F5C2C wds:Q39820638-AA1B460E-7B6A-426B-8302-E9AF3CF89950 wds:Q44947287-6ABD7D15-EC5E-4610-AECA-45E6B69B16E4 wds:Q66903038-49E61953-FD0D-40DA-A808-D5384DD78C3B wds:Q34538835-369C902C-2EDA-4C79-9276-5EE9EA06118E wds:Q39897360-BF1D4B34-5C0A-412F-AACB-A6847A934433 wds:Q41529295-E1FBE278-E6FC-437F-8EF5-9A0EB7A52FA3 wds:Q66965745-B3B83D4B-986F-4904-B6F5-79D9D3427991 wds:Q40032519-F0EEA6C9-6E72-4EA4-8F71-FDF2C6FD46D8 wds:Q33899039-D6470EB5-B878-4451-9F1C-0AFB507A1DE2 wds:Q39713418-D7200FBC-24F3-4AEB-9868-962239989208 wds:Q45139381-B1C5F06C-1DF0-4782-80C2-39DC63279BDE wds:Q40272437-43F32699-BA63-43B9-A954-5D3A6B18065C wds:Q41844442-B42F198B-7A80-40F4-81FB-54F6C1424109 wds:Q44790518-CC847E90-CC06-4AD1-B994-7D7369F4A2EF wds:Q34302932-1501A99C-498F-4B49-8EC7-393F5CBB5A8E wds:Q38704422-2D824EC8-0C38-4EDC-A5B8-2861D6626747 wds:Q66904108-2AC6FFF1-3893-4981-A0C7-51D895CEAFDD wds:Q67315826-D712C251-78C4-4986-A722-CA8156B9A607 wds:Q66890716-1B0F52CD-F24C-4F38-A3DE-3277801E135F wds:Q93652183-06F96E7F-D83A-41CE-9C41-16B605FCB138 wds:Q53773049-516938D7-6A47-41D5-B960-8B0566D22C42 wds:Q67427502-93E67404-05C8-4433-A5E4-3A731C17BB4E wds:Q39133846-00132ACE-1489-4BAC-9234-E07D56894D95 wds:Q35640416-F0252DCE-834B-4F80-B77B-843FA36931CA wds:Q37030666-22938E79-73FD-4EAD-AE99-1F0AE80E0F26 wds:Q40087323-52BA0A30-6006-4100-A30E-BC9FA59F516F

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software